Wide Ranks

ALGS

Aligos Therapeutics, Inc.

22.99

Top Statistics
Market Cap 82 M Forward PE -1.77 Revenue Growth -60.80 %
Current Ratio 3.81 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.1800 Enterprise / Revenue 2.78 Price To Sales Trailing12 Months 13.75
Profitability
Profit Margins 0.00 % Operating Margins -1586.37 %
Balance Sheet
Total Cash 74 M Total Cash Per Share 20.88 Total Debt 9 M
Total Debt To Equity 18.23 Current Ratio 3.81 Book Value Per Share 15.07
All Measures
Short Ratio 73.00 % Message Board Id finmb_581475891 Shares Short Prior Month 82817
Return On Equity -1.47 City South San Francisco Uuid bbc2c389-779c-3f10-ac5a-f071b0904bd5
Previous Close 21.35 First Trade Date Epoch Utc 1 B Book Value 15.07
Beta 2.12 Total Debt 9 M Volume 275920
Price To Book 1.53 Last Split Date 1 B Fifty Two Week Low 6.76
Total Cash Per Share 20.88 Total Revenue 5 M Shares Short Previous Month Date 1 B
Target Median Price 75.00 Audit Risk 3 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -1586.37 % Target Mean Price 103.33
Net Income To Common -76953000 Short Percent Of Float 0.1297 Implied Shares Outstanding 3 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 567120
Average Volume10days 567120 Total Cash 74 M Next Fiscal Year End 1 B
Revenue Per Share 1.00 Held Percent Insiders 0.1780 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 21.35 Target Low Price 60.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 11.25 Open 22.61 Free Cashflow -49061000
State CA Dividend Yield 0.00 % Return On Assets -0.6732
Time Zone Short Name EST Board Risk 8 Trailing Eps -7.25
Day Low 21.51 Address1 One Corporate Drive Shares Outstanding 3 M
Compensation Risk 10 Price Hint 2 Target High Price 175.00
Website https://www.aligos.com 52 Week Change 0.3137 Average Volume 273842
Forward Eps -11.92 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 357.50 % Last Split Factor 1:25 Regular Market Day High 23.70
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 18.23
Fifty Two Week High 30.00 Day High 23.70 Shares Short 291505
Regular Market Open 22.61 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 2.78 Revenue Growth -60.80 % Shares Percent Shares Out 0.0812
Operating Cashflow -84998000 Currency USD Time Zone Full Name America/New_York
Market Cap 82 M Is_nasdaq_100 False Zip 94080
Quote Type EQUITY Industry Biotechnology Long Name Aligos Therapeutics, Inc.
Overall Risk 9 Regular Market Day Low 21.51 Held Percent Institutions 0.4886
Current Price 22.99 Address2 2nd Floor Enterprise To Ebitda -0.1800
Financial Currency USD Current Ratio 3.81 Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 419891
Two Hundred Day Average 15.43 Governance Epoch Date 1 B Enterprise Value 16 M
Price To Sales Trailing12 Months 13.75 Forward PE -1.77 Regular Market Volume 275920
Ebitda -92684000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.

Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.

In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus.

The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co.

, Ltd.

to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors.

It also has a clinical collaboration with Xiamen Amoytop Biotech Co.

, Ltd.

Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.